Skip to main content

Table 5 Bleb failure risk factors and failure results per group

From: Preliminary results of Preserflo Microshunt versus Preserflo Microshunt and Ologen implantation

Demographics

Group A

Group B

No. of eyes operated total

25

25

Prior ocular surgeries

Phacoemulsification

Phacoemulsification

Ethnicity of patients

Caucasian

Caucasian

No. of female patients

18

15

Age (years)

77.58 ± 7.62

75.64 ± 12.61

No. of male patients

7

10

Bleb revision surgery at 6 months (failure rate)

1 (4%)

3 (12%)

  1. MMC mitomycin C
  2. Group A: Preserflo Microshunt with MMC 0.2 mg/ml
  3. Group B: Preserflo Microshunt with MMC 0.2 mg/ml and Ologen